Search Results - "Lyris, Nikos"

Matching-Adjusted Indirect Comparison of the 52-Week Efficacy of Bimekizumab Versus Secukinumab and Ixekizumab for the Treatment of Radiographic Axial Spondyloarthritis by Maksymowych, Walter P., Thom, Howard, Mørup, Michael F., Taieb, Vanessa, Willems, Damon, Lyris, Nikos, Gaffney, Karl

“…Introduction A previous network meta-analysis established 16-week relative efficacy with bimekizumab, an inhibitor of interleukin (IL)-17F in addition to…”
Get full text

Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison by Mease, Philip J., Warren, Richard B., Nash, Peter, Grouin, Jean-Marie, Lyris, Nikos, Willems, Damon, Taieb, Vanessa, Eells, Jason, McInnes, Iain B.

“…Introduction Matching-adjusted indirect comparisons (MAICs) were used to compare the efficacy of bimekizumab and secukinumab 150 mg and 300 mg at 52 weeks for…”
Get full text

Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison by Warren, Richard B., McInnes, Iain B., Nash, Peter, Grouin, Jean-Marie, Lyris, Nikos, Willems, Damon, Taieb, Vanessa, Eells, Jason, Mease, Philip J.

“…Introduction Matching-adjusted indirect comparisons (MAIC) were used to assess the relative efficacy of bimekizumab 160 mg every 4 weeks (Q4W) compared to…”
Get full text

Comparative Effectiveness of Bimekizumab and Ustekinumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison by Mease, Philip J., Warren, Richard B., Nash, Peter, Grouin, Jean-Marie, Lyris, Nikos, Taieb, Vanessa, Eells, Jason, McInnes, Iain B.

“…Introduction A matching-adjusted indirect comparison (MAIC) was conducted to assess the relative efficacy at 52 weeks (Wk52) of bimekizumab 160 mg every…”
Get full text

Comparative Effectiveness of Bimekizumab and Risankizumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison by Mease, Philip J., Warren, Richard B., Nash, Peter, Grouin, Jean-Marie, Lyris, Nikos, Willems, Damon, Taieb, Vanessa, Eells, Jason, McInnes, Iain B.

“…Introduction The relative efficacy of bimekizumab and risankizumab in patients with PsA who were biologic disease-modifying anti-rheumatic drug naïve (bDMARD…”
Get full text

Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase III studies by Kristensen, Lars Erik, Tillett, William, Nash, Peter, Coates, Laura C., Mease, Philip J., Ogdie, Alexis, Gisondi, Paolo, Ink, Barbara, Prickett, Adam R., Bajracharya, Rajan, Taieb, Vanessa, Lyris, Nikos, Lambert, Jérémy, Walsh, Jessica A.

“…Background: Psoriatic arthritis (PsA) is a chronic inflammatory disease that causes pain and fatigue, reduces physical function, and negatively impacts…”
Get full text

The cost-effectiveness of a bimekizumab versus IL-17A inhibitors treatment-pathway in patients with active axial spondyloarthritis in Scotland by Mørup, Michael F, Taieb, Vanessa, Willems, Damon, Rose, Micah, Lyris, Nikos, Lamotte, Mark, Gerlier, Laetitia, Thom, Howard

“…To estimate the cost-effectiveness of a treatment-pathway initiated with bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F…”
Get more information